This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, L. Articles by Pang, S. Search for Related Content PubMed PubMed Citation Articles by Zhang, L. Articles by Pang, S.

Characterization of Two Novel Homozygous Missense Mutations Involving Codon 6 and 259 of Type II 3ß-Hydroxysteroid Dehydrogenase (3ßHSD) Gene Causing, Respectively, Nonsalt-Wasting and Salt-Wasting 3ßHSD Deficiency Disorder¹

Department of Pediatrics, University of Illinois College of Medicine (L.Z., Y.N., Y.T.C., S.P.), Chicago, Illinois 60612; Department of Pediatrics, Baylor College of Medicine (K.C.C.), Houston, Texas 77030; Department of Pediatrics, Winthrop University Hospital, State University of New York (M.C.M.), Long Island, New York 11501; and Department of Reproductive and Developmental Sciences (Clinical Biochemistry), University of Edinburgh (J.I.M.), EH3 9YW Edinburgh, Scotland

Address all correspondence and requests for reprints to: Dr. Songya Pang, Department of Pediatrics (M/C 856), University of Illinois, 840 South Wood Street, Chicago, Illinois 60612.

We identified two homozygous missense mutations in the human type II 3ß-hydroxysteroid dehydrogenase (3ßHSD) gene, the first in codon 6 of exon II [CTT (Leu) to TTT (Phe)] in a male infant with hyperpigmented scrotum and hypospadias, raised as a male and no apparent salt-wasting since neonatal age, and the second in codon 259 of exon IV [ACG (Thr) to ATG (Met)] in a male pseudohermaphrodite with labial scrotal folds, microphallus, chordee, and fourth degree hypospadias, raised as a female and with salt-wasting disorder since neonatal age. In vitro transient expression of mutant type II 3ßHSD complementary DNAs of L6F, T259M, as well as T259R for comparison was examined by a site-directed mutagenesis and transfection of construct into COS-1 and COS-7 cells. Northern blot analysis revealed expression of similar amounts of type II 3ßHSD messenger ribonucleic acid from the COS-1 cells transfected by L6F, T259M, T259R, and wild-type (WT) complementary DNAs. Western immunoblot analysis revealed a similar amount of L6F mutant protein compared to WT enzyme from COS-1 cells, but neither L6F from COS-7 cells nor T259M or T259R mutant protein in COS-1 or COS-7 cells was detectable. Enzyme activity in intact COS-1 cells using 1 µmol/L pregnenolone as substrate in the medium after 6 h revealed relative conversion rates of pregnenolone to progesterone of 46% by WT enzyme, 22% by L6F enzyme, and 8% by T259M enzyme and less than 4% activity by T259R enzyme. Using 1 µmol/L dehydroepiandrosterone as substrate, the relative conversion rate of dehydroepiandrosterone to androstenedione after 6 was 89% by WT enzyme, 35% by L6F enzyme, 5.1% by T259M enzyme and no activity by T259R enzyme. However, the L6F mutant 3ßHSD activity, despite its demonstration in the intact cells, was not detected in homogenates of COS-1 cells or in immunoblots of COS-7 cells, suggestive of the relatively unstable nature of this protein in vitro, possibly attributable to the decreased 3ßHSD activity. In the case of T259M and T259R mutations, consistently undetectable proteins in both COS cells despite detectable messenger ribonucleic acids indicate severely labile proteins resulting in either no or very little enzyme activity, and these data further substantiate the deleterious effect of a structural change in this predicted putative steroid-binding domain of the gene. In conclusion, the findings of the in vitro study of mutant type II 3ßHSD enzyme activities correlated with a less severe clinical phenotype of nonsalt-wasting and a lesser degree of genital ambiguity in the patient with homozygous L6F mutation compared to a more severe clinical phenotype of salt-wasting and severe degree of genital ambiguity in the patient with homozygous T259M mutation in the gene.

This article has been cited by other articles:

				J. Simard, M.-L. Ricketts, S. Gingras, P. Soucy, F. A. Feltus, and M. H. Melner Molecular Biology of the 3{beta}-Hydroxysteroid Dehydrogenase/{Delta}5-{Delta}4 Isomerase Gene Family Endocr. Rev., June 1, 2005; 26(4): 525 - 582. [Abstract] [Full Text] [PDF]

				L. M. Mermejo, L. L. K. Elias, S. Marui, A. C. Moreira, B. B. Mendonca, and M. de Castro Refining Hormonal Diagnosis of Type II 3{beta}-Hydroxysteroid Dehydrogenase Deficiency in Patients with Premature Pubarche and Hirsutism Based on HSD3B2 Genotyping J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1287 - 1293. [Abstract] [Full Text] [PDF]

				S. Kosel, S. Burggraf, R. Fingerhut, H. G. Dorr, A. A. Roscher, and B. Olgemoller Rapid Second-Tier Molecular Genetic Analysis for Congenital Adrenal Hyperplasia Attributable to Steroid 21-Hydroxylase Deficiency Clin. Chem., February 1, 2005; 51(2): 298 - 304. [Abstract] [Full Text] [PDF]

				S. Pang, W. Wang, B. Rich, R. David, Y. T. Chang, G. Carbunaru, S. E. Myers, A. F. Howie, K. J. Smillie, and J. I. Mason A Novel Nonstop Mutation in the Stop Codon and a Novel Missense Mutation in the Type II 3{beta}-Hydroxysteroid Dehydrogenase (3{beta}-HSD) Gene Causing, Respectively, Nonclassic and Classic 3{beta}-HSD Deficiency Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2556 - 2563. [Abstract] [Full Text] [PDF]

				C. Lutfallah, W. Wang, J. I. Mason, Y. T. Chang, A. Haider, B. Rich, M. Castro-Magana, K. C. Copeland, R. David, and S. Pang Newly Proposed Hormonal Criteria via Genotypic Proof for Type II 3{beta}-Hydroxysteroid Dehydrogenase Deficiency J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2611 - 2622. [Abstract] [Full Text] [PDF]